Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 6/20 | 0.39 |
| ▸ | CCKBR | P32239 | 6/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114033 | 0.96 | GLP1R (0.52) | GLP1RTLR2CCKARCCKBRALB | |
| SCHEMBL8106168 | 0.92 | GLP1R (0.48) | GLP1RTLR2CCKARCCKBRALB | |
| SCHEMBL12972441 | 0.91 | GLP1R (0.68) | GLP1RTLR2CCKARCCKBRNOD1 | |
| SCHEMBL8115663 | 0.90 | GLP1R (0.51) | GLP1RCCKARCCKBRALBSIRT5 | |
| SCHEMBL14438806 | 0.89 | GLP1R (0.70) | GLP1RTLR2CCKARCCKBRNOD1 | |
| SCHEMBL15259287 | 0.89 | GLP1R (0.70) | GLP1RTLR2CCKARCCKBRNOD1 | |
| SCHEMBL12972439 | 0.87 | GLP1R (0.61) | GLP1RTLR2CCKARCCKBRSIRT6 | |
| SCHEMBL14550380 | 0.87 | GLP1R (0.58) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14685801 | 0.85 | GLP1R (0.48) | GLP1RTLR2CCKARCCKBRALB | |
| SCHEMBL13577576 | 0.85 | GLP1R (0.76) | GLP1RCCKARCCKBRNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632753-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2014-01-21 | — | — | US | disclosed |
| US-7854919-B2 | Multivalent constructs for therapeutic and diagnostic applications | Bracco, Suisse SA (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | GLP1R 2595/4885TLR2 3487/4885CCKAR 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.